There is strong evidence that psilocybin could play a very important role in a new generation of treatments for those with a variety of mental and physical health conditions. Research into this incredibly promising area is held back by psilocybin's classification as a 'schedule 1' drug. Schedule 1 is for drugs deemed to have 'no medical value'. Psilocybin does not belong there. PAR.global campaigns for the rescheduling of psilocybin as part of our belief in evidence-based drugs policy. Unjustified barriers to research on this chemical should be safely removed. Go to our website https://www.par.global/ to sign the gov.uk petition and follow the campaign. PAR.global is a UK non-profit working as part of the global campaign to reschedule psilocybin.